Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Monsanto to consider...

    Monsanto to consider Bayer's revised proposal for acquisition

    Written by savita thakur thakur Published On 2016-07-17T15:42:20+05:30  |  Updated On 17 July 2016 3:42 PM IST
    Monsanto to consider Bayers revised proposal for acquisition

    New Delhi : US-biotech major Monsanto said its board would review the revised nearly USD 65-billion takeover bid from German pharma and chemical giant Bayer AG.


    In May, Bayer AG had announced a USD 62-billion all-cash offer to acquire Monsanto Co but the same was rejected by the latter.


    Bayer had raised its all cash offer to Monsanto shareholders from USD 122 to USD 125/share. It also offered a USD 1.5-billion reverse anti-trust break fee.


    Monsanto has a significant presence in India and has played a key role in increasing cotton output through its genetically modified (GM) technologies.


    In a filing to the BSE, Monsanto India informed that its parent firm Monsanto Company "has received a revised, non-binding proposal from Bayer AG for a potential acquisition of Monsanto."


    "The Board of Directors of Monsanto will review the proposal, in consultation with its financial and legal advisors," the filing added.


    Monsanto said it would have no further comment until its Board of Directors has completed its review. "There is no assurance that any transaction will be entered into or consummated, or on what terms".


    Monsanto has three entities in India Monsanto India Ltd (MIL), Monsanto Holdings Pvt Ltd (MHPL) and JV firm Mahyco Monsanto Biotech India Ltd (MMBL) with a staff strength of more than 1,000.


    While rejecting Bayer's offer on May 24, Monsanto Company had termed the Bayer AG proposal "as incomplete and financially inadequate" but said that the company was open to "continued and constructive conversations".


    "We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer's business, Monsanto Chairman and CEO Hugh Grant had said.


    "However, the current proposal significantly undervalues our company and also does not adequately address or provide reassurance for some of the potential financing and regulatory execution risks related to the acquisition," Grant had said.

    AcquisitionBayer AGgenetically modifiedGMMahyco Monsanto Biotech India LtdMHPLMILMMBLMonsanto
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok